No profile data available.
AN2 Therapeutics, Inc. (ANTX) is a healthcare company in the antibacterial pharmaceuticals industry, based in Menlo Park, United States, with about 21 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$35.17 million. Its market capitalization was $166.04 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
AN2 Therapeutics reported $0 in revenue for fiscal year 2025.
$166.04 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include Insmed Incorporated (INSM), Vaxcyte, Inc. (PCVX), BGM Group Ltd. (BGM), Armata Pharmaceuticals, Inc. (ARMP).